{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
clindamycin phosphate
to a specific field?
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125347
(2009)
Source URL:
First approved in 2009
Source:
BLA125347
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2004
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
BLA125812
(2024)
Source URL:
First approved in 2024
Source:
BLA125812
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Investigational
Source:
NCT01414153: Phase 2 Interventional Completed Exudative Age-related Macular Degeneration
(2012)
Source URL:
Class:
CONCEPT
Status:
Other
Class:
CONCEPT